335 related articles for article (PubMed ID: 20382527)
1. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
2. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Liu L; Norman MH; Lee M; Xi N; Siegmund A; Boezio AA; Booker S; Choquette D; D'Angelo ND; Germain J; Yang K; Yang Y; Zhang Y; Bellon SF; Whittington DA; Harmange JC; Dominguez C; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1868-97. PubMed ID: 22320327
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS; Zhang L; Schmidt R; Cai ZW; Wei D; Williams DK; Lombardo LJ; Trainor GL; Xie D; Zhang Y; An Y; Sack JS; Tokarski JS; Darienzo C; Kamath A; Marathe P; Zhang Y; Lippy J; Jeyaseelan R; Wautlet B; Henley B; Gullo-Brown J; Manne V; Hunt JT; Fargnoli J; Borzilleri RM
J Med Chem; 2008 Sep; 51(17):5330-41. PubMed ID: 18690676
[TBL] [Abstract][Full Text] [Related]
11. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
13. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
Lee J; Han SY; Jung H; Yang J; Choi JW; Chae CH; Park CH; Choi SU; Lee K; Ha JD; Lee CO; Ryu JW; Kim HR; Koh JS; Cho SY
Bioorg Med Chem Lett; 2012 Jun; 22(12):4044-8. PubMed ID: 22579487
[TBL] [Abstract][Full Text] [Related]
17. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
[TBL] [Abstract][Full Text] [Related]
18. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
19. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
20. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
